Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJE4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,491
Award facts
- Contract value 100% obligated
- $33,491.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $33,491.48 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 ml vials. The delivery order, awarded on December 1, 2025, with an ultimate completion date of December 22, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025.
The PPV-G GEN V contract, valued at $499,999,999 through December 31, 2036, positions DMS Pharmaceutical Group as a critical regional prime vendor contractor within the broader $30.3 billion Defense Logistics Agency pharmaceutical acquisition strategy designed to support Department of Defense healthcare operations globally. The Keytruda delivery order represents one of numerous delivery orders issued to DMS Pharmaceutical Group under this prime vendor contract, reflecting the company's established capability to supply both specialty pharmaceuticals and routine medical products to military healthcare facilities. No subcontractors are identified in the award documentation, with DMS Pharmaceutical Group serving as the sole prime contractor responsible for fulfillment.
Quick answers
Who was awarded contract SPE2DR26FDJE4?
SPE2DR26FDJE4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FDJE4 worth?
The government has obligated $33,491 on SPE2DR26FDJE4.
Is contract SPE2DR26FDJE4 an order under another contract?
Yes. SPE2DR26FDJE4 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJE4 competed?
The extent of competition for SPE2DR26FDJE4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award